Biohit Oyj Class B · OMXHEX:BIOBV
Biohit Oyj Class B — Technical Presentation
26 slides from Biohit Oyj Class B's technical presentation
Slide 1: GastroPanel as the First-Line Diagnostic Test for Dyspeptic Symptoms and Gastric Cancer Risk Screening
GastroPanel® (Panel of Biomarkers) as the First-Line Diagnostic Test for Dyspeptic Symptoms and in Screening for the Risk Groups of Gastric Cancer Prof. Osmo Suovaniemi, MD, PhD Chairman of the Board Biohit Oyj, Finland
Slide 2: GastroPanel – a test for stomach health
GastroPanel® – a test for stomach health
Slide 3: GastroPanel test – a panel of 4 biomarkers
GastroPanel® test – a panel of 4 biomarkers Pepsinogen I & II; Pepsinogen I/II ratio are biomarkers of gastric corpus Esophagus Amidated gastrin-17 is biomarker of antrum (G cells), together with Pepsinogen II Corpus H. pylori IgG antibodies are markers of HP- associated gastritis (antrum & corpus)
Slide 4: GastroPanel test – indications for use
GastroPanel® test – indications for use The First-Line Diagnostic Test for Patients with Dyspeptic Complaints For Screening of the Subjects at Increased Risk for Gastric Cancer
Slide 5: GastroPanel – dyspepsia (stomach pain or discomfort)
GastroPanel® – dyspepsia (Stomach pain or discomfort) Dyspepsia is not a specific symptom Affects some 20-40% of the population Correct diagnosis is not possible by symptoms alone H.pylori infection and atrophic gastritis (AG), the most important clinical conditions behind dyspepsia Gastroscopy is t
Slide 6: GastroPanel – risk factors of gastric cancer
GastroPanel® – risk factors of gastric cancer Helicobacter pylori infection: Relative risk= 3.0–13.3 Atrophic gastritis: Relative risk = up to 90 Ref: smoking and lung cancer: OR=12 HPV16 and cervical cancer: OR>400
Slide 7: Correa's cascade
“Correa’s cascade” ? Gastric Adenocarcinoma G17 Diffuse type Gastric Normal Chronic Intestinal Adenocarcinoma mucosa gastritis metaplasia Dysplasia Intestinal type antrum Atrophic gastritis corpus PGI, PGI/II ratio Correa P. Cancer Res 1992;52:6735-6740.
Slide 8: HP and AG - two diseases, one diagnostic test: WHY?
HP and AG - two diseases, one diagnostic test GastroPanel: WHY?
Slide 9: Phenotype of gastritis - risk for GC is different
Phenotype of gastritis - risk for GC is different RISK OF ULCER: RISK OF GC: corpus corpus 0 1 2 3 4 0 1 2 3 4 antrum 0 1 0.5 0.1 0.1 0.1 0 1 1 1 2 5 1 10 10 2 1 0.5 1 1 2 2 2 5 2 22 22 3 2 1 2 2 2 2 3 5 3 26 26 3 2 1 3 2 2 4 5 10 4 26 26 3 2 1 4 18 18 36 36 90 0=normal; 1=non-atrophic gastritis; 2=
Slide 10: HP and AG - two diseases, one diagnostic test: HOW?
HP and AG- two diseases, one diagnostic test GastroPanel: HOW?
Slide 11: Atrophic gastritis in the corpus
Atrophic gastritis in the corpus Protein Atrophic Corpus Gastritis: G-17 HCl ↓ Blood PGI ↓ circulation Antrum PG II↓ G-17
Slide 12: Atrophic gastritis in the antrum
Atrophic gastritis in the antrum Protein Normal Corpus: PGI and PGII normal or high G-17↓ Atrophic Blood Antrum circulation Gastritis: G-17 ↓
Slide 13: GastroPanel – results reported by GastroSoft
GastroPanel® – results reported by GastroSoft®
Slide 14: GastroPanel – the diagnostic algorithm
GastroPanel® – the diagnostic algorythm *The GastroPanel report contains a more detailed interpretation. Source: Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Agreus L, Kuipers E, Kupcinskas L, Malfertheiner P, DI Mario F, Leja M, Mahachai V, Yar
Slide 15: GastroPanel – stomach is healthy
GastroPanel® – stomach is healthy H.pylori G-17 PGI PGII PGI/PGII Antrum Corpus EIU pmol/l µg/l µg/l 30 1-7 30 - 160 3 – 15 3 - 20 2 8 75 10.1 N N All GastroPanel biomarkers are normal !! Risk of cancer or peptic ulcer is nil – irrespective of age. Gastroscopy does not give any significant informati
Slide 16: GastroPanel – severe atrophy in the corpus
GastroPanel® – severe atrophy in the corpus H.pylori G-17 PGI PGII PGI/PGII Antrum Corpus EIU pmol/l µg/l µg/l 30 1-7 30 - 160 3 – 15 3 - 20 150 363 5 3.5 1.4 N N PGI is low indicating that corpus is severely atrophic. The PGI/PGII ratio (1.4) is low (below 3,0) Amidated G-17 is high indicating that
Slide 17: GastroPanel – three categories of risk
GastroPanel® – three categories of risk “Healthy”, normal stomach mucosa: No risk of gastric cancer or ulcer Non-atrophic H.pylori (Hp+) gastritis: High ulcer risk, low cancer risk. Atrophic gastritis (Hp+ or Hp-): High cancer risk, low ulcer risk. High risk of mal- absorption of vitamin B12, calciu
Slide 18: GastroPanel – three approaches of management
GastroPanel® – three approaches of management “Healthy”, normal stomach mucosa: No need for prompt gastroscopy(save costs) Non-atrophic H.pylori (Hp+) gastritis: Patient and physician may decide of further treatment and examinations. Consider eradication of H.pylori! Atrophic gastritis (Hp+ or Hp-):
Slide 19: GastroPanel – a rationale for using
GastroPanel® – a rational for using H.pylori-infection is causally related to AG, and treatment is indicated (Maastricht IV recommendations) GastroPanel provides an easy, cheap and comprehensive non- endoscopic diagnostic option GastroPanel provides more information than is possible to obtain by H.p
Slide 20: GastroPanel – the cost-effective diagnostic tool
GastroPanel® – the cost-effective diagnostic tool Benefits of GastroPanel are two-fold: Detects the subjects with healthy stomach Detects the patients at increased risk for cancer/ulcer Healthy stomach Patient with dyspeptic complaints GastroPanel® Gastroscopy
Slide 21: Acetium Capsule
Acetium® Capsule TO THOSE WITH ACID FREE STOMACH • Atrophic gastritis • Use of PPI-drugs • Operated stomach • Chronic Helicobacter pylori infection No other similar • May cure atrophic preparation gastritis (further studies are needed) available
Slide 22: Acetium Lozenge
Acetium® Lozenge • To smokers –Eliminates >90% of carcinogenic acetaldehyde from saliva • Harm reduction (L-cysteine and Xylitol eliminate carcinogenic acetaldehyde in saliva) • May help stop tobacco smoking (further studies are needed) • No other similar preparation available
Slide 23: Study Protocols Provided by BIOHIT Oyj
Study Protocols Provided by BIOHIT Oyj Clinical Trial with the Biohit HealthCare GastroPanel® Assay for Early Detection of Patients at Risk for Gastric Cancer. (GastroPanel Clinical Study) Biohit HealthCare GastroPanel® Assay In Screening of Patients at Risk for Gastric Cancer. (GastroPanel Screenin
Slide 24: GastroPanel does not have the serious medical problems of other tests
APPENDIX 1 The state-of-the-art, safe and economic GastroPanel examination does not have any of the following serious medical problems: The 13C urea breath test (UBT), stool antigen test and antibody tests do not detect atrophic gastritis which is caused by H. pylori infection or an autoimmune disea
Slide 25: Appendix 1, continues
APPENDIX 1, continues Atrophic gastritis in the gastric corpus and PPI therapy cause anacidity (aclorhydria) of the stomach. The risk of pneumonias and, in senior citizens, even the risk of fatal intestinal infections (such as giardiasis, malaria, Clostridium difficile and E. coli EHEC) may increase
Slide 26: Thank you very much for your attention!
Thank you very much for your attention!